Donut Chart from Scientific Research

Concordance (percentage in light blue) between the recommendations agreed upon by the MTB and those inferred from information provided by diagnostic levels level 1 (detailed clinical data, routine molecular testing data in melanoma (BRAF, NRAS and c-KIT mutations) and DigiPath data), level 2 (level 1 plus large panel NGS), or level 3 (all TuPro technology nodes, n = 9), and fraction of actual TuPro-driven therapy decisions (i.e., 50% of the applied drugs are supported by markers measured by TuPro).

DOI